SNX-111 neuron-specific calcium channel blocker: The indication for the Phase I/II trial will be expanded to include a wider population with cancer pain, and to

Neurex Corp. (NXCO), Menlo Park, Calif. Product: SNX-111 neuron-specific calcium channel blocker Indication: Intractable pain Status: The indication for the Phase I/II trial will be expanded to incl...